股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上巿股份 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,608,000 | RMB | | | 1 RMB | | 4,608,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 4,608,000 | RMB | | | 1 RMB | ...

Core Viewpoint - The revenue of Tongyuan Kang Pharmaceutical-B (02410.HK) is primarily dependent on the exclusive licensing agreement with Lijun Pharmaceutical for the development and commercialization of the multi-target small molecule tyrosine kinase inhibitor TY-2136b in Greater China, with no milestone payments triggered as of June 30, 2025 [1] Financial Performance - The company's revenue for the six months ending June 30, 2024, and June 30, 2025, is reported as RMB 0 [1] - Research and development costs for the six months ending June 30, 2025, amounted to RMB 88.758 million, a decrease of 35.6% compared to RMB 137.758 million for the same period in 2024, primarily due to reduced trial and testing expenses [1] - The loss for the six months ending June 30, 2025, decreased to RMB 114 million from RMB 220 million for the same period in 2024 [1]

Group 1 - The core point of the article is that Dr. Meng Xiaoying has resigned from her position as a non-executive director of the company, effective from August 31, 2025, to dedicate more time to other business commitments [1] Group 2 - The resignation indicates a shift in the company's board composition, which may impact its strategic direction and governance [1] - The company may need to consider appointing a new non-executive director to fill the vacancy left by Dr. Meng [1] - This change could reflect broader trends in the industry regarding board member commitments and the balancing of multiple business interests [1]

同源康医药-B(02410)公布，孟晓英博士已提出辞任公司非执行董事，自2025年8月31日起生效，以投放 更多时间从事其他业务承担。 ...

Group 1 - The company reported a mid-year performance for 2025, with R&D costs of 88.758 million yuan, a year-on-year decrease of 35.6%, and administrative expenses of 38.775 million yuan, down 3.3%. The loss attributable to shareholders was approximately 112 million yuan, a reduction of 48.79% year-on-year [1] - Since its establishment in 2017, the company has developed a pipeline of 11 candidate drugs, including the core product TY-9591, which is currently preparing for a conditional NDA application for the treatment of EGFR mutation lung cancer brain metastases and is undergoing a registration Phase III clinical trial in China for the treatment of EGFR L858R mutation locally advanced or metastatic NSCLC [1] Group 2 - The company will focus on market demand and deepen the research and innovation of self-developed cutting-edge products, leveraging AI models to enhance collaboration with top international teams for efficient new molecule development [2] - A new solid dosage form factory project is underway, which will add tablet and capsule production lines, with an expected annual capacity of 150 million tablets or capsules, supporting clinical drug production and partial commercialization of TY-9591 [2] - The commercial team has been initially established with core management members possessing extensive experience in promotion and commercialization, aiming to systematically build a sales and marketing system through internal efforts and external partnerships [3]

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 李鈞博士 顧虹博士 蔣鳴昱博士 何超先生 朱向陽博士 獨立非執行董事 張森泉先生 冷瑜婷博士 許文青博士 沈秀華博士 1 董事會設立四個委員會。下表提供各董事會成員所在委員會的成員資料。 （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 吳豫生博士 非執行董事 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 何超先生 | | | | | | | 朱向陽博士 | | | | | | | 張森泉先生 | | C | M | M | | | 冷瑜婷博士 | | M | C | M | | | 許文青博士 | | | ...

理財產品認購 董事會宣佈，作為資金運作的一部分，本集團已於2025年2月18日至2025年3月 15日期間認購中信銀行發行的五項理財產品。 投資於基金及贖回基金權益 於2025年1月2日，本公司亦投資於6項基金（以獨立投資組合公司權益及有限合 夥基金權益形式）。該等權益其後由本公司贖回（詳見本公告）。 上市規則的涵義 由於認購事項的性質相似，且均於12個月內與同一金融機構中信銀行訂立，故 就根據上市規則第14.22條計算相關百分比率而言，相關理財產品的相應本金應 與本集團當時持有相關金融機構的理財產品尚未到期結餘合併計算。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 須予披露交易 認購理財產品； 投資及贖回基金權益；及 更新全球發售閒置資金用途 由於有關與同一金融機構進行的認購事項的最高適用百分比率（定義見上市規 則 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 截至2025年6月30日止六個月中期業績公告； 非執行董事辭任；及 建議修訂組織章程細則 | 財務摘要 | | | | | | --- | --- | --- | --- | --- | | | 截至6月30日止六個月 | | | | | | 2025年 | 2024年 | 變動 | | | 人民幣千元 | | 人民幣千元 | 人民幣千元 | % | | （未經審計） | | （未經審計） | | | | 研發成本 | (88,758) | (137,758) | 49,000 | -35.6 | | 行政開支 | (38,775) | (40,100) | 1,325 | -3.3 | | 期內總全面虧損 | (114,065) | (219,533) | 105,468 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3][4]. Summary by Category Increase in Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Hang Seng China Enterprises (02828) with an increase of 5.48%, bringing the total holding to 6.10% - Tracker Fund of Hong Kong (02800) with an increase of 4.07%, totaling 4.76% - Anjoy Foods (02648) with an increase of 1.74%, now at 15.81% [2] - Other notable increases include: - Angelalign Technology (06699) +1.66% to 23.03% - Ganfeng Lithium (01772) +1.44% to 34.51% - East China Environmental Protection (00895) +1.44% to 43.67% [2] Decrease in Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Kinglong Motor Group (06680) with a decrease of 3.39%, now at 24.56% - Interstellar Technology (01725) with a decrease of 2.02%, totaling 10.16% - Goldwind (02208) with a decrease of 1.48%, now at 41.84% [3] - Other notable decreases include: - ZTE Corporation (00763) -1.35% to 56.09% - Longpan Technology (02465) -1.08% to 49.62% [3] Five-Day Changes - Over the last five trading days, the companies with the largest increases in holdings are: - Lens Technology (06613) +6.93% to 13.85% - ZTE Corporation (00763) +5.92% to 56.09% - Tongyu Pharmaceutical-B (02410) +5.40% to 14.72% [4] - The companies with the largest decreases in holdings over the same period include: - Hang Seng China Enterprises (02828) -14.01% to 6.10% - Tracker Fund of Hong Kong (02800) -4.36% to 4.76% [4] Twenty-Day Changes - In the last twenty days, the companies with the largest increases in holdings are: - Meizhong Jiahe (02453) +12.09% to 37.34% - Changfei Optical Fiber (06869) +10.66% to 54.73% - Tongyu Pharmaceutical-B (02410) +8.30% to 14.72% [5] - The companies with the largest decreases in holdings over the same period include: - Yisou Technology (02550) -10.13% to 47.88% - Chongqing Steel (01053) -5.27% to 31.55% [6]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase in stock price, rising by 6.23% to HKD 16.37, following the announcement of a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huiyu Pharmaceutical's subsidiary, Sichuan Huichenxing [1] Group 1 - The company plans to appoint Sichuan Huichenxing as the exclusive agent for TY-9591 in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this potential agency agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and the agreement is expected to leverage Sichuan Huiyu's extensive sales and agency network [1] Group 2 - Sichuan Huiyu is a mature pharmaceutical enterprise with a complete industrial chain and rich experience in drug agency and sales in China [1] - The arrangement is anticipated to enhance sales and revenue for TY-9591, accelerate market penetration, and reduce the costs associated with establishing new sales channels [1] - Collaborating with a well-known pharmaceutical company is expected to strengthen the company's brand image [1]